Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display & Cocktail

20P - Interim safety and efficacy results of a phase II clinical trial on trametinib and low-dose dabrafenib in patients with advanced BRAFV600 wild-type melanoma

Date

02 Mar 2020

Session

Poster Display & Cocktail

Presenters

Gil Awada

Citation

Annals of Oncology (2020) 31 (suppl_1): S10-S13. 10.1016/annonc/annonc85

Authors

G. Awada1, J.K. Schwarze1, E. Reijmen2, C. Goyvaerts2, G. Fasolino3, S. Aspeslagh1, B. Neyns1

Author affiliations

  • 1 Department Of Medical Oncology, Universitair Ziekenhuis Brussel, 1090 - Brussels/BE
  • 2 Laboratory Of Molecular & Cellular Therapy, Vrije Universiteit Brussel, 1090 - Brussels/BE
  • 3 Department Of Ophtalmology, Universitair Ziekenhuis Brussel, 1090 - Brussels/BE
More

Resources

Abstract 20P

Preclinical and clinical data suggest MEK-inhibition (MEKi) to be effective in NRAS-mutant (mt) and NRAS wild-type (wt) melanoma. However, MEKi causes considerable cutaneous treatment-related adverse events (TRAE) which are less present if MEKi is combined with BRAFi.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings